Gemphire Therapeutics Inc.
(NASDAQ : GEMP)

( )
GEMP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Company
1.47%50.331.4%$1034.51m
PFEPfizer Inc.
0.21%42.560.9%$1010.27m
MRKMerck & Co., Inc.
0.62%76.070.6%$1000.40m
JNJJohnson & Johnson
1.48%131.000.6%$986.58m
ABBVAbbVie, Inc.
2.97%89.792.2%$600.74m
LLYEli Lilly and Company
-1.90%116.901.0%$523.00m
AZNAstraZeneca PLC Sponsored ADR
0.72%36.551.3%$196.86m
NVSNovartis AG Sponsored ADR
0.42%89.000.2%$164.18m
GSKGlaxoSmithKline plc Sponsored ADR
0.21%39.060.2%$127.98m
NVONovo Nordisk A/S Sponsored ADR Class B
0.83%48.050.1%$70.06m
SNYSanofi Sponsored ADR
-1.36%41.480.2%$37.73m
LCILannett Company, Inc.
2.14%7.6537.0%$11.86m
AKTXAkari Therapeutics Plc Sponsored ADR
-5.21%1.821.7%$0.05m
EPIXESSA Pharma Inc
1.76%3.850.1%$0.03m

Company Profile

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.